Traditional Approaches for Company Valuation Are Flawed for Valuing In Vivo Gene Therapy Companies

The era of gene therapy has begun. In recent years, potentially breakthrough datasets and rapidly expanding company pipelines have begun to overshadow the unfulfilled promise characteristic of the gene therapy sector in decades prior. One barometer for progress in the space can be seen in stock mark...

Descripción completa

Detalles Bibliográficos
Autores principales: Amusa, Gbolahan, Feehley, Taylor, Bitok, J. Kipchirchir, Livshits, Geulah, Gertsik, Natalya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2018
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312046/
https://www.ncbi.nlm.nih.gov/pubmed/30547692
http://dx.doi.org/10.1089/humc.2018.29037.gam

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312046/
https://www.ncbi.nlm.nih.gov/pubmed/30547692
http://dx.doi.org/10.1089/humc.2018.29037.gam

Ejemplares similares